The Bull Rankings scorecard — our quality-growth score is 87.7 / 100, built from three pillars scored 0–100: Quality 80, Growth 95, Value 88 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free cash flow shrinking 25% or more next year, then recovering toward 4% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Oscar Health’s current price is a fair bet on a growth engine that is already outpacing the market’s own expectations. The Bull Rankings model gives OSCR a 87.7/100 quality‑growth score, with Growth at 95, Quality at 80, and Value at 88. The strongest pillar—Growth—shows that the company is pulling in revenue at 27.5 % YoY, a pace that far exceeds the 25.7 P/E it trades at, which sits near the Healthcare median. The price already discounts free‑cash‑flow growth to a 25 % decline in year one, tapering to 4 % by year ten, a trajectory that is below the recent 27.5 % revenue growth. That gap means the market is pricing in a slowdown, yet the company’s recent earnings beat and AI‑driven outlook suggest it can sustain the high growth for longer. In short, OSCR is a growth play that is already priced with a modest upside.
What the business actually is
Oscar Health sells health plans to individuals, families, employees, and small groups across the United States. Its core revenue comes from premiums on these plans, but the company also monetizes its technology stack. The Oscar platform powers other players in the healthcare system, while the Campaign Builder platform offers engagement and recommendation tools for providers and payors. Reinsurance products, brokerage services, and an enrollment platform for brokers and consumers round out the offering. The growth engine is clearly the plan sales segment, which has expanded into 150+ metro areas by 2027, as noted in the latest Zacks piece.
Why it can (and does) keep compounding
Oscar’s moat is two‑fold: a tech‑first customer experience and a data‑driven underwriting model. The company’s free‑cash‑flow of $4.4 billion in the trailing twelve months shows it can fund growth without external debt, and its debt‑to‑equity of 0.23 keeps leverage low. Profit margins sit at 3.6 %, modest but improving, and ROE is a solid 34.3 %. These figures indicate that the firm is generating healthy returns on capital and can reinvest in its platform. Competitors would need to replicate both the technology stack and the customer acquisition engine, a process that takes years and significant capital.
The valuation question
At a P/E of 25.7, Oscar trades near the Healthcare median, suggesting the market is not overpaying for its earnings. However, the reverse‑DCF tells a different story: the current price implies a free‑cash‑flow growth that starts at a 25 % decline and eases to 4 % by year ten. That trajectory is below the 27.5 % revenue growth the company just delivered. In other words, the market is already pricing in a slowdown, yet the company’s recent earnings beat and AI‑driven outlook hint that it can maintain higher growth for longer. The value pillar of 88 places the stock on the cheap side of its peers, reinforcing that the price is not inflated by hype. The PEG ratio of 1.94, while above 1, is still reasonable given the high growth trajectory.
The bear case
The most compelling risk is that Oscar’s high growth is not sustainable. The reverse‑DCF’s assumption of a 25 % decline in free‑cash‑flow growth in year one is already a pessimistic view. If the company fails to keep its revenue growth above 27.5 % or if its profit margin slips below 3.6 %, the implied valuation would collapse. A concrete signal would be a drop in the 27.5 % revenue growth figure or a widening of the 3.6 % margin. The Zacks article highlights that the stock trades at a 4.94 price‑to‑book ratio, far above the industry average of 2.64, suggesting that disciplined underwriting is still a challenge. If Oscar cannot control costs and maintain underwriting discipline, the premium could evaporate.
What would change our mind
- Revenue growth falling below 27.5 % – a single quarter of slower growth would undermine the growth pillar and shift the model’s score downward.
- Profit margin slipping below 3.6 % – a margin erosion would erode the quality pillar and raise doubts about the sustainability of free‑cash‑flow.
- Debt‑to‑equity rising above 0.23 – higher leverage would increase financial risk and could force the company to cut back on technology investment, weakening its moat.
If any of these thresholds are breached, the Bull Rankings model would downgrade OSCR’s quality‑growth score, and the stock would likely trade closer to its 52‑week low of $10.69.